categories: CD and Related Antigens (Human)

Mouse Monoclonal to CD138 / Syndecan 1

B-A38 (IgG1)

Product No.	Form	Quantity	Price
10-520-C025	azide free	0.025 mg	choose region
10-520-C100	azide free	0.1 mg	choose region
1F-520-T025	FITC	25 tests	choose region
1F-520-T100	FITC	100 tests	choose region
1P-520-T025	PE	25 tests	choose region
1P-520-T100	PE	100 tests	choose region
A7-520-T025	Alexa Fluor® 700	25 tests	choose region
A7-520-T100	Alexa Fluor® 700	100 tests	choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

CD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix components and influence many developmental processes. CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury. It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells. Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics. Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.

Gene Locus: 2p24.1

Specificity

The antibody B-A38 recognizes CD138 (syndecan 1), a 65-70 kDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes.

Immunogen

U266 human peripheral blood myeloma cell line

Species Reactivity: Human Negative Species:	Applications: Flow Cytometry Immunohistochemistry Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	General references Hayashida K, Johnston DR, Goldberger O, Park P.W.: Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem. 2006 Aug 25;281(34):24365-74. [Abstract] [Full Text] Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, Min C.K.: Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer. 2007 Aug 15;121(4):741-50. [Abstract] Manakil JF, Seymour GJ, Bartold P.M.: Effect of cytokine and antigen stimulation on peripheral blood lymphocyte syndecan-1 expression. Oral Microbiol Immunol. 2007 Aug;22(4):272-6. [Abstract] Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T, Noma T.: Differential expression of syndecan isoforms during mouse incisor amelogenesis. J Med Invest. 2007 Aug;54(3-4):331-9. [Abstract] Ojeh N, Hiilesvuo K, Wärri A, Salmivirta M, Henttinen T, Määttä A.: Ectopic expression of syndecan-1 in basal epidermis affects keratinocyte proliferation and wound re-epithelialization. J Invest Dermatol. 2008 Jan;128(1):26-34. [Abstract] Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M.: Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2008 Jan 7. [Abstract] Product Specific References Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD: The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007 Sep 15;110(6):2041-8. [Abstract] Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC: G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest. 2007 Oct;117(10):3107-17. [Abstract] [Full Text] *Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, Ettinger R: Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol. 2007 Nov 1;179(9):5886-96. [Abstract]

Species Reactivity:

Human

Negative Species:

Applications:

Flow Cytometry
Immunohistochemistry

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

*Hayashida K, Johnston DR, Goldberger O, Park P.W.: Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem. 2006 Aug 25;281(34):24365-74. [Abstract] [Full Text]

*Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, Min C.K.: Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer. 2007 Aug 15;121(4):741-50. [Abstract]

*Manakil JF, Seymour GJ, Bartold P.M.: Effect of cytokine and antigen stimulation on peripheral blood lymphocyte syndecan-1 expression. Oral Microbiol Immunol. 2007 Aug;22(4):272-6. [Abstract]

*Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T, Noma T.: Differential expression of syndecan isoforms during mouse incisor amelogenesis. J Med Invest. 2007 Aug;54(3-4):331-9. [Abstract]

*Ojeh N, Hiilesvuo K, Wärri A, Salmivirta M, Henttinen T, Määttä A.: Ectopic expression of syndecan-1 in basal epidermis affects keratinocyte proliferation and wound re-epithelialization. J Invest Dermatol. 2008 Jan;128(1):26-34. [Abstract]

*Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M.: Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2008 Jan 7. [Abstract]

Product Specific References

*Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD: The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007 Sep 15;110(6):2041-8. [Abstract]

*Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC: G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest. 2007 Oct;117(10):3107-17. [Abstract] [Full Text]

*Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, Ettinger R: Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol. 2007 Nov 1;179(9):5886-96. [Abstract]

For research use only. Not for drug, diagnostic or other use.

Related Products

Mouse IgG1 Isotype Control

PRODUCTS